<?xml version='1.0' encoding='utf-8'?>
<document id="29074892"><sentence text="Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study."><entity charOffset="31-44" id="DDI-PubMed.29074892.s1.e0" text="Levothyroxine" /></sentence><sentence text="Eprotirome, a liver specific thyroid hormone agonist, was shown to induce significant increases in markers of liver injury along with a modest decrease in atherogenic lipids and lipoproteins" /><sentence text=" To get more insight into whether these effects on liver parameters were compound specific or the effect of mimicking thyrotoxicosis, we studied the effects of supra-physiological levothyroxine dosages on liver parameters, lipids and lipoproteins"><entity charOffset="180-193" id="DDI-PubMed.29074892.s3.e0" text="levothyroxine" /></sentence><sentence text=" We used data of a single-blinded, randomized controlled crossover trial" /><sentence text=" Herein, healthy volunteers received levothyroxine or no medication for 14 days"><entity charOffset="37-50" id="DDI-PubMed.29074892.s5.e0" text="levothyroxine" /></sentence><sentence text=" Thyroid hormone excess did not induce clinically relevant changes in liver parameters, while significant reductions in total cholesterol, low-density lipoprotein-cholesterol as well as apolipoprotein-B levels were observed in the intervention periods compared with the control periods"><entity charOffset="126-137" id="DDI-PubMed.29074892.s6.e0" text="cholesterol" /><entity charOffset="163-174" id="DDI-PubMed.29074892.s6.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.29074892.s6.e0" e2="DDI-PubMed.29074892.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29074892.s6.e0" e2="DDI-PubMed.29074892.s6.e1" /></sentence><sentence text=" Supra-physiological thyroid hormone levels did not induce clinically relevant increases in markers of liver injury after 2 weeks of exposure, while it reduced total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B levels"><entity charOffset="166-177" id="DDI-PubMed.29074892.s7.e0" text="cholesterol" /><entity charOffset="203-214" id="DDI-PubMed.29074892.s7.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.29074892.s7.e0" e2="DDI-PubMed.29074892.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29074892.s7.e0" e2="DDI-PubMed.29074892.s7.e1" /></sentence><sentence text=" This suggests that the effects of eprotirome on liver parameters in previous studies were either off-target and compound specific or due to drug-drug interaction at the level of the liver" /><sentence text=" The results of our study are relevant for the development of novel thyroid hormone agonists to reduce atherogenic lipoproteins" /><sentence text="" /></document>